skip to content


Issue No. 4 | February 22, 2018

News and Features

AIDSinfo Releases Fact Sheet on Biktarvy, a New Combination Drug to Treat Certain Adults with HIV

On February 7, 2018, the Food and Drug Administration (FDA) approved Biktarvy, a new antiretroviral drug to treat HIV infection in adults. The three-drug (bictegravir, emtricitabine, and tenofovir alafenamide), fixed-dose combination tablet is a complete regimen for adults who have never taken HIV medicines before. Biktarvy may also provide a treatment alternative for adults on a current HIV regimen who meet specific criteria. For information on Biktarvy, including details on who can take the drug, please see the AIDSinfo Biktarvy fact sheet [en español].

Do you want to learn more about HIV medicines? Check out the AIDSinfo FDA-Approved HIV Medicines fact sheet and infographic.


Updates to the HHV-8 Section of the Adult and Adolescent Opportunistic Infections Guidelines

The Human Herpesvirus-8 (HHV-8) section of the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents was updated on February 21, 2018. In this revision, the epidemiology of HHV-8 infection and HHV-8 related malignancies have been revised to reflect current data, and information about the newly described clinical syndrome, the KSHV inflammatory cytokine syndrome (KICS), is provided. Treatment recommendations for multicentric Castleman's disease have been updated.


HHS Panel on Antiretroviral Guidelines for Adults and Adolescents Welcomes New Panel Members

The HHS Panel on Antiretroviral Guidelines for Adults and Adolescents (a working group of the Office of AIDS Research Council) is pleased to welcome the following new scientific members to the Panel who will begin a 4-year term starting in April 2018.

  • Curt Beckwith, MD (Brown University, Providence, RI)
  • R. Douglas Bruce, MD, MA, MS (Cornell Scott-Hill Health Center/Yale University, New Haven, CT)
  • Geetanjali Chander, MD, MPH (Johns Hopkins University, Baltimore, MD)
  • Eric Daar, MD (University of California Los Angeles, Los Angeles, CA)
  • Steven C. Johnson, MD (University of Colorado, Aurora, CO)
  • Tonia Poteat, PhD, MPH, PA-C (Johns Hopkins University, Baltimore, MD)
  • Asa Radix, MD, MPH (Callen-Lorde Community Health Center/New York University, New York, NY)
The Panel would also like to welcome Virginia Sheikh, MD, MHS, of the U.S. Food and Drug Administration (FDA) who joined the Panel in January 2018 as a representative from the FDA.

The Panel would like to express our gratitude and appreciation to the following outgoing members for the many years of dedication and contributions in the development of these guidelines:
  • Charles Hicks, MD (formerly University of California San Diego, San Diego, CA)
  • Richard Price, MD (University of California San Francisco, San Francisco, CA)
  • Adam Sherwat, MD (U.S. Food and Drug Administration, Silver Spring, MD)
  • Jeff Taylor (AIDS Treatment Activists Coalition, Palm Springs, CA)
  • Zelalam Temesgen, MD (Mayo Clinic, Rochester, MN)


Recent HIV News from NIH